Dermorphin Reconstitution Calculator

No. Dermorphin has no regulatory approval as a human medicine in any jurisdiction. A randomized, placebo-controlled trial reported in 1985 found intrathecal dermorphin superior to placebo and to morphine for postoperative pain (RCT), but the result went almost completely uncited and the compound never re-entered clinical development. It remains an experimental peptide, an analytical target in doping control, and a Class I banned substance in equine sport.

Dermorphin is far more potent on a per-unit basis, roughly 670-fold more potent than morphine in the mouse tail-flick assay after intracerebroventricular dosing (animal), and the 1985 trial described analgesia superior to intrathecal morphine (RCT). Forensic and veterinary literature describes lower tolerance and addiction liability than morphine, but core opioid toxicities remain: vagally mediated apnea (animal), dose-dependent respiratory depression (animal), and development of tolerance and physical dependence in rats.

Route selection is critical. Intrathecal injection is the only route with published human efficacy data (RCT). Subcutaneous delivery of the peripherally restricted analog DALDA (dermorphin [D-Arg2, Lys4] (1-4) amide) produced analgesia at 1–10 mg/kg without CNS side effects in rat models of burn pain, nerve injury, and spinal cord injury (animal). Intranasal dosing was active for stabilized analogs at microgram doses (0.5–1.0 µg/kg, animal), while oral activity required cyclic 2,5-DKP-modified analogs (animal). Intravenous bolus dermorphin triggers immediate apnea and is the least tolerated route (animal).

No established human dose exists outside the historical intrathecal trial. Published animal reference doses: DALDA 1–10 mg/kg s.c. dose-dependently reversed evoked and spontaneous pain in burn-injured rats; 1 mg/kg s.c. blocked heat hypersensitivity after spinal cord injury in mice; efficacy against thermal vs mechanical pain differed up to 70-fold in nerve-ligated rats; intranasal analog D2 was active at 0.5–1.0 µg/kg; intracerebroventricular dermorphin showed bimodal respiratory effects from 10 pmol/kg to 10 nmol/kg (animal). Practitioner-reported human use: intranasal 20–100 µg; SC/IM 250–500 µg; onset 5–20 min; duration 1–3 h (community protocol). Rodent mg/kg doses do not translate directly to humans.

The dominant risk is respiratory arrest. Intravenous bolus dermorphin reliably produces immediate, vagally mediated, μ1-opioid receptor-dependent apnea in rats (animal), and a dermorphin-based hybrid peptide induced apnea in 70% of anesthetized rats (animal). Effects are dose-bimodal: low i.c.v. doses stimulate respiration and locomotion via μ1 receptors; high doses depress respiration via μ2 receptors (animal). Central administration is also epileptogenic, with seizures originating in ventral hippocampal CA3 (animal). In humans, dermorphin inhibits the spinal nociceptive flexion reflex and releases growth hormone and prolactin. Peripherally restricted analogs such as DALDA avoid CNS effects in animal models.

Yes, with an unusual twist. Dermorphin induces tolerance, physical dependence, and cross-tolerance with morphine in rats (animal). However, μ1-receptor desensitization after a single dose is rapid: the apneic response occurs only on the first injection, and dermorphin pretreatment blocks fentanyl-induced apnea (animal). DALDA relieved burn pain without evidence of drug addiction in rats (animal). No human tolerance or dependence data exist.

Analgesia is described as long-lasting in the intrathecal trial (RCT), and synthetic tetrapeptide analogs produced potent, long-lasting analgesia after a single subcutaneous dose in rodents (animal). Respiratory suppression after intravenous dermorphin recovers far faster than after fentanyl (0.5 min vs 30 min) (animal). No modern human duration-of-action data are available.

Yes. Urine screening and confirmation methods detect dermorphin and its (1–4) fragment at 2.5 ng/ml; newer UPLC-HRMS panels screen 63 small peptides, including dermorphin and analogs, with limits of detection of 0.010–0.473 ng/ml. The major metabolite YAFG-OH (dermorphin 1-4) is recommended as the primary target analyte for misuse detection. Dermorphin use has been documented in human and equine sport and is prohibited in horse racing.